SCHEMBL4568045

SCHEMBL4568045

CCOC(=O)c1cccc(C(O)c2c(-c3cncs3)[nH]c3cc(OC)ccc23)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
NPC1 O15118 5/20 0.39
KDM4E B2RXH2 4/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
GABRA1 P14867 4/20 0.37
GABRG2 P18507 4/20 0.37
GABRB3 P28472 4/20 0.37
GABRA5 P31644 4/20 0.37
GABRA3 P34903 4/20 0.37
GABRA2 P47869 4/20 0.37
LMNA P02545 2/20 0.37
GABRP O00591 2/20 0.37
GABRD O14764 2/20 0.37
GABRB1 P18505 2/20 0.37
GABRB2 P47870 2/20 0.37
GABRA4 P48169 2/20 0.37
GABRE P78334 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568205 0.82 MAPT (0.40) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL3701212 0.74 MMP2 (0.43) MAPTNPC1KDM4ERAB9AALDH1A1
SCHEMBL3715217 0.73 MAPT (0.43) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568329 0.73 KDM4E (0.41) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL4568312 0.73 TUBB4A (0.39) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568328 0.73 MAPK13 (0.38) MAPTNPC1RAB9ACNR1TP53
SCHEMBL4568321 0.72 MAPT (0.44) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568326 0.71 AXL (0.38) MAPTKDM4ERAB9AALDH1A1HPGD
SCHEMBL3705305 0.71 TUBB4A (0.42) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL3701562 0.71 GPR17 (0.40) KDM4EALDH1A1HPGDHSD17B10TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
EP-2474530-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2012-07-11 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MAPT 3199/4885NPC1 1150/4885KDM4E 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.